查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
製藥市場- 成長，未來展望，競爭分析，2024年～2032年
市場調查報告書
商品編碼
1510314

製藥市場- 成長，未來展望，競爭分析，2024年～2032年

Pharmerging Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
出版日期: | 出版商: Acute Market Reports | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

醫藥市場是指新興國家的醫藥市場，預計將快速成長，並在全球醫藥產業中發揮越來越重要的作用。這些市場的特點是人口眾多、中產階級不斷壯大、醫療基礎設施改善以及獲得醫療服務的機會增加，這些都推動了藥品需求。預計到 2032 年，藥品市場將成長 11.5%。醫藥市場的簡要概述強調了影響其成長的幾個關鍵因素。首先，新興國家的經濟發展帶來了可支配收入的增加和健康意識的提高，從而促進了對醫療服務和產品的需求增加。其次，這些地區的政府正在大力投資醫療基礎設施，包括醫院和診所，以增加獲得各種治療的機會。此外，旨在鼓勵本地藥品生產的監管改革和政府支持政策正在刺激國內企業的成長並吸引外資。最後，慢性病的盛行率不斷上升，加上人口的快速成長，增加了擴大對醫療保健服務和藥物的需求。

經濟成長與醫療支出增加

製藥市場的主要驅動力之一是新興國家強勁的經濟成長，導致醫療保健支出增加。中國、印度和巴西等國家的國內生產毛額正在成長，可支配所得和生活水準也隨之提高。經濟繁榮使更多的人能夠購買醫療保健服務和藥品。這些國家的政府政策透過增加醫療保健預算撥款來進一步支持這一趨勢，以實現全民覆蓋並改善醫療保健基礎設施。醫療保健投資的激增不僅提高了治療的有效性，而且提高了人們的整體健康意識，導致對藥物的需求增加。

擴大醫療基礎設施

醫藥市場的主要商機在於醫療基礎設施的擴張。新興國家正在迅速發展醫院、診所和分銷網絡，以隨著人口的增長改善獲得醫療保健的機會。這種擴張從城市地區延伸到歷史上醫療服務不足的農村地區。醫療設施的增加需要相應增加藥品供應，這為製藥公司進入新市場和建立強大的分銷管道創造了巨大的機會。

監理異質性

管制異質性是醫藥市場的主要限制因素。新興市場通常具有多樣化且不斷發展的監管框架，各國之間差異很大。這種多樣性可能會給尋求同時在多個市場推出產品的製藥公司帶來課題。應對這些不同的監管環境需要大量資源和專業知識，這可能會延遲產品發布或增加市場進入成本。

與本地廠商的競爭

藥品市場的一個主要課題是與當地藥品製造商的競爭。這些本地製造商通常更了解本地市場動態和監管細微差別。他們也可能與當地醫療保健系統建立了關係，並受到當地消費者的青睞。此外，由於勞動力和原材料較便宜，當地製造商通常能夠以較低的成本生產藥品，這使得國際公司難以在價格上競爭。如此激烈的競爭要求跨國製藥公司在產品供應、市場策略、定價模式等方面進行創新，以在這些地區建立並擴大業務。

依產品：市場區隔

當醫藥市場依產品分類時，可以看出藥品和保健品是兩個重要的類別。由於新興市場疾病負擔的增加和醫療保健機會的擴大，對藥品的持續需求，藥品始終是最高的收入。該細分市場受益於需要持續藥物幹預的慢性病的流行以及傳染病所需的急性治療。同時，包括服務、醫療保健 IT 和醫療設備在內的醫療保健產業預計將具有最高的複合年增長率 (CAGR)。這種快速增長的推動因素包括政府努力改善衛生基礎設施、增加對醫院設施的私人投資以及隨著世界轉向更有效率的醫療保健服務系統而對遠距醫療和數位醫療解決方案的重視。

依指標：市場區隔

依適應症劃分的市場區隔包括生活型態疾病、癌症/自體免疫疾病、傳染病等。癌症和自體免疫疾病領域預計將產生最高的收入，這主要是由於治療成本的上升和針對這些複雜疾病的藥物創新的進步。隨著人口老化和西方生活方式變得更加普遍，新興市場中這些疾病的盛行率不斷上升，也加劇了這一趨勢。相反，治療糖尿病和高血壓等生活方式相關疾病的領域預計複合年增長率最高。這一增長的主要驅動力是由於飲食習慣的改變、城市化進程的加速和久坐生活方式的增加，這些疾病在新興市場人口中迅速增加。

依分銷管道：市場區隔

從分銷通路的市場區隔來看，醫院和零售藥局是主要參與者。醫院在這一領域的收入最高，因為它們是提供住院和門診護理的主要醫療服務提供中心。綜合治療的需要和專科用藥的需要，為醫院帶來了巨大的利潤。由於自我藥療趨勢的上升、城鄉地區藥房網路的改善和藥房網路的擴張，預計零售藥房的複合年增長率最高。此外，人們對連鎖藥局藥品零售的信任度不斷提高，以及對仿製藥的接受度不斷提高，在這一增長中發揮關鍵作用。此外，由於線上訂購的便利性和互聯網服務的日益普及，電子商務管道正在迅速普及，這表明新興市場藥品分銷領域的消費者行為可能發生轉變。

區域洞察

地理趨勢突顯了醫藥市場各個地區的顯著成長，其中亞太地區在複合年增長率 (CAGR) 和銷售額方面均處於領先地位。 2023年，中國和印度等國家由於人口眾多、醫療成本上升以及藥品製造能力不斷擴大而主導了市場收入。由於政府的支持性政策和中產階級的崛起，這些國家已成為藥品創新和生產的中心。展望2024年至2032年的預測期間，由於都市化進程加快、醫療基礎設施改善以及慢性病增加，亞太地區預計將維持成長率領先地位。在類似的醫療改革和經濟發展趨勢的推動下，拉丁美洲和東歐預計也將顯著成長，但與亞太地區相比，其整體市場佔有率仍然較小。

競爭趨勢

從競爭趨勢來看，市場競爭的特徵是主要製藥公司之間的激烈競爭和區域新進入者的動態進入。 2023 年，雅培實驗室、荷蘭皇家飛利浦公司、羅氏公司、默克公司、諾華公司、強生公司、梯瓦製藥工業有限公司、阿斯特捷利康、葛蘭素史克公司、Lupin、塔塔諮詢服務有限公司。這些公司專注於策略聯盟、併購和收購，以鞏固其市場地位，同時大力投資研發，以創新複雜疾病的新療法。在 2024 年至 2032 年的預測期內，這些公司預計將繼續專注於滲透未開發的市場，提供顯著的成長機會，特別是對於仿製藥和生物製劑。此外，在印度和中國等地區，當地製造商預計將透過利用成本優勢和當地監管支援來加強其市場佔有率，從而加劇競爭格局。這些趨勢正在塑造製藥市場的策略方向，迫使公司不斷適應這些動態地區不斷變化的醫療保健需求和監管環境。

本報告回答的主要問題

影響醫藥市場成長的主要微觀和宏觀環境因素有哪些？

現在和預測期內產品細分和地區的主要投資領域是什麼？

2032 年之前的預估與市場預測

哪個細分市場在預測期間內複合年增長率最快？

哪個細分市場擁有較大的市場佔有率，為什麼？

低收入和中等收入國家是否投資醫藥市場？

醫藥市場最大的區域市場是哪一個？

亞太地區、拉丁美洲和中東/非洲等新興市場的市場趨勢和動態是什麼？

推動醫藥市場成長的主要趨勢是什麼？

主要競爭對手有哪些以及他們提高在全球製藥市場影響力的關鍵策略？

目錄

第一章前言

  • 報告內容
    • 報告的目的
    • 對象者
    • 主要的提供
  • 市場區隔
  • 調查手法
    • 階段Ⅰ-二次調查
    • 階段Ⅱ-一次調查
    • 階段Ⅲ-有學識者檢討
    • 前提條件
    • 採用的方法

第2章 摘要整理

第3章 製藥市場:競爭分析

  • 主要供應商的市場定位
  • 供應商採用的策略
  • 主要的產業策略
  • 層級分析:2023 vs 2032

第4章 製藥市場:常量分析和市場動態

  • 簡介
  • 全球製藥市場金額 2022-2032
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析
  • 波特的五力分析
    • 供應商電力
    • 買主電力
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭企業間的敵對關係
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 科技的形勢
    • 法律上的形勢
    • 社會形勢

第5章 製藥市場:各產品 2022-2032

  • 市場概要
  • 成長·收益分析:2023 vs 2032
  • 市場區隔
    • 醫藥品
      • 品牌處方藥
      • 學名藥
      • 成藥
    • 醫療保健
      • 醫療設備
      • 診斷設備
      • 其他(IT及記錄管理)

第6章 製藥市場:各適應症 2022-2032

  • 市場概要
  • 成長·收益分析:2023 vs 2032
  • 市場區隔
    • 文明病
    • 癌症和自體免疫疾病
    • 感染疾病
    • 其他

第7章 製藥市場:各流通管道 2022-2032

  • 市場概要
  • 成長·收益分析:2023 vs 2032
  • 市場區隔
    • 醫院
    • 診所
    • 零售藥局
    • 電子商務
    • 藥妝店

第8章 北美的製藥市場 2022-2032

  • 市場概要
  • 製藥市場:各產品 2022-2032
  • 製藥市場:各適應症 2022-2032
  • 製藥市場:各流通管道 2022-2032
  • 製藥市場:各地區 2022-2032
    • 北美
      • 美國
      • 加拿大
      • 其他北美地區

第9章 英國和歐洲聯盟的製藥市場 2022-2032

  • 市場概要
  • 製藥市場:各產品 2022-2032
  • 製藥市場:各適應症 2022-2032
  • 製藥市場:各流通管道 2022-2032
  • 製藥市場:各地區 2022-2032
    • 英國和歐洲聯盟
      • 英國
      • 德國
      • 西班牙
      • 義大利
      • 法國
      • 其他歐洲地區

第10章 亞太地區的製藥市場 2022-2032

  • 市場概要
  • 製藥市場:各產品 2022-2032
  • 製藥市場:各適應症 2022-2032
  • 製藥市場:各流通管道 2022-2032
  • 製藥市場:各地區 2022-2032
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 其他亞太地區

第11章 南美的製藥市場 2022-2032

  • 市場概要
  • 製藥市場:各產品 2022-2032
  • 製藥市場:各適應症 2022-2032
  • 製藥市場:各流通管道 2022-2032
  • 製藥市場:各地區 2022-2032
    • 南美
      • 巴西
      • 墨西哥
      • 其他南美國家地區

第12章 中東·非洲的製藥市場 2022-2032

  • 市場概要
  • 製藥市場:各產品 2022-2032
  • 製藥市場:各適應症 2022-2032
  • 製藥市場:各流通管道 2022-2032
  • 製藥市場:各地區 2022-2032
    • 中東·非洲
      • GCC
      • 非洲
      • 其他中東·非洲地區

第13章 企業簡介

  • Abbott Laboratories
  • Koninklijke Philips N.V.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • AstraZeneca
  • GlaxoSmithKline plc
  • Lupin
  • Tata Consultancy Services Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Huadong Medicine Co. Ltd.
  • 其他的主要企業
Product Code: 599-07-24

The pharmerging market refers to pharmaceutical markets in emerging economies that are expected to grow rapidly and play an increasingly significant role in the global pharmaceutical industry. These markets are characterized by their large populations, rising middle class, improving healthcare infrastructure, and increasing access to medical care, which collectively drive the demand for pharmaceutical products. The pharmerging market is expected to grow at 11.5% by 2032. A brief overview of the pharmerging market highlights several key factors influencing its growth. First, economic development in these countries leads to higher disposable incomes and greater health awareness, contributing to a higher demand for healthcare services and products. Second, governments in these regions are making significant investments in healthcare infrastructure, including hospitals and clinics, which increases accessibility to a wider range of medical treatments. Additionally, regulatory reforms and supportive government policies aimed at encouraging local production of pharmaceuticals stimulate the growth of domestic companies and attract foreign investment. Finally, the increasing prevalence of chronic diseases, coupled with a burgeoning population, underscores the need for expanded healthcare services and pharmaceutical products.

Economic Growth and Increased Healthcare Spending

One of the primary drivers of the pharmerging market is the robust economic growth observed in emerging economies, which has led to increased healthcare spending. As countries like China, India, and Brazil experience GDP growth, there is a corresponding rise in disposable incomes and living standards. This economic prosperity allows more people to afford healthcare services and pharmaceuticals. Government policies in these countries further support this trend by increasing healthcare budget allocations, aiming to provide universal health coverage and improve healthcare infrastructure. This surge in healthcare investment not only boosts the availability of medical treatments but also enhances the overall health awareness among the populace, leading to increased demand for pharmaceutical products.

Expansion of Healthcare Infrastructure

A significant opportunity within the pharmerging market lies in the expansion of healthcare infrastructure. Emerging economies are rapidly building hospitals, clinics, and distribution networks to make healthcare more accessible to their growing populations. This expansion is not limited to urban areas but extends to rural regions, which historically have been underserved. The increase in healthcare facilities necessitates a corresponding increase in pharmaceutical supplies, creating substantial opportunities for pharmaceutical companies to penetrate new markets and establish robust distribution channels.

Regulatory Heterogeneity

Regulatory heterogeneity serves as a key restraint in the pharmerging market. Emerging markets often have diverse and evolving regulatory frameworks that can vary significantly from one country to another. This variability can pose challenges for pharmaceutical companies looking to launch products simultaneously in multiple markets. Navigating these different regulatory environments requires significant resources and expertise, which can delay product launches and increase the cost of market entry.

Competition with Local Manufacturers

A major challenge in the pharmerging market is the competition posed by local pharmaceutical manufacturers. These local companies often have a better understanding of the regional market dynamics and regulatory nuances. They also benefit from established relationships within local healthcare systems and may be viewed more favorably by local consumers. Additionally, local manufacturers can often produce pharmaceuticals at a lower cost due to cheaper labor and materials, making it difficult for international companies to compete on price. This intense competition requires multinational pharmaceutical companies to innovate in terms of product offerings, market strategies, and pricing models to gain a foothold and expand their presence in these regions.

Market Segmentation by Product

In the pharmerging market, segmentation by product reveals that Pharmaceuticals and Healthcare are two significant categories. Pharmaceuticals consistently drive the highest revenue due to the persistent need for medications, driven by an increasing burden of diseases and expanding healthcare access in emerging markets. This segment benefits from both the widespread chronic conditions requiring ongoing pharmaceutical interventions and the acute treatments needed for communicable diseases. On the other hand, the Healthcare segment, encompassing services, healthcare IT, and medical equipment, is projected to experience the highest Compound Annual Growth Rate (CAGR). This surge is fueled by governmental efforts to improve healthcare infrastructure, increasing private investments in hospital facilities, and a growing emphasis on telemedicine and digital health solutions in response to the global push for more efficient healthcare delivery systems.

Market Segmentation by Indication

Market segmentation by indication includes Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and others. The segment for Cancer and Autoimmune Diseases is expected to witness the highest revenue, largely due to the high cost of treatments and ongoing pharmaceutical innovation aimed at these complex conditions. Additionally, the increasing prevalence of these diseases in emerging markets as populations age and adopt more Western lifestyles contributes to this trend. Conversely, the segment dealing with Lifestyle Diseases such as diabetes and hypertension is anticipated to register the highest CAGR. This growth is primarily driven by the rapid increase in these conditions among populations in emerging markets, spurred by changing diets, increasing urbanization, and more sedentary lifestyles.

Market Segmentation by Distribution Channel

Regarding the market segmentation by distribution channel, Hospitals and Retail Pharmacies are key players. Hospitals account for the highest revenue within this segment, as they are the primary health service delivery points offering both inpatient and outpatient care. The comprehensive care requirements and the need for specialized pharmaceuticals fuel their dominant revenue position. Retail Pharmacies are projected to see the highest CAGR, attributed to the growing trend of self-medication, increased accessibility, and the expansion of pharmacy networks across urban and rural areas. Moreover, the rising confidence in pharmaceutical retail through chain pharmacies and the growing acceptance of generic drugs play crucial roles in this growth. Additionally, e-commerce channels are rapidly gaining traction due to the convenience of online ordering and the increasing penetration of internet services, indicating a potential shift in consumer behavior in the pharmaceutical distribution landscape in emerging markets.

Regional Insights

In the pharmerging market, geographic trends highlight significant growth across various regions, with Asia-Pacific leading in terms of both the highest Compound Annual Growth Rate (CAGR) and revenue generation. In 2023, countries like China and India dominated the market revenue due to their large populations, increasing healthcare expenditure, and expanding pharmaceutical manufacturing capabilities. These nations have become hubs for pharmaceutical innovation and production, driven by supportive government policies and a rising middle class. Looking forward to the forecast period of 2024 to 2032, Asia-Pacific is expected to maintain its lead in growth rates due to ongoing urbanization, healthcare infrastructure improvements, and the increasing prevalence of chronic diseases. Latin America and Eastern Europe are also expected to witness notable growth, driven by similar trends of healthcare reforms and economic development, though their overall market share remains smaller compared to Asia-Pacific.

Competitive Trends

In terms of competitive trends, the pharmerging market is characterized by a mix of intense competition among leading pharmaceutical companies and dynamic entries by new regional players. In 2023, top players like Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca, GlaxoSmithKline plc, Lupin, Tata Consultancy Services Ltd., Sun Pharmaceutical Industries Ltd., Huadong Medicine Co., Ltd. showcased substantial revenues by leveraging their extensive product portfolios and robust distribution networks. These companies focused on strategic alliances, mergers, and acquisitions to consolidate their market positions, while also investing heavily in research and development to innovate new treatments for complex diseases. Looking into the forecast period of 2024 to 2032, these companies are expected to continue their emphasis on expanding into untapped markets, particularly focusing on generic drugs and biologics, which are anticipated to offer substantial growth opportunities. Additionally, local manufacturers in regions such as India and China are expected to strengthen their market presence by capitalizing on cost advantages and local regulatory support, thereby intensifying the competitive landscape. These trends are poised to define the strategic directions of the pharmerging market, with companies constantly adapting to the evolving healthcare demands and regulatory environments in these dynamic regions.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Pharmerging market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Pharmerging market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Product

  • Pharmaceuticals

Branded Prescription Drugs

Generic Drugs

Branded Generics

Unbranded Generics

OTC Drugs

  • Healthcare

Medical Devices

Diagnostic Instruments

Others (IT and Record Management)

Indication

  • Lifestyle Diseases
  • Cancer and Autoimmune Diseases
  • Infectious Diseases
  • Others

Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • E-commerce
  • Drugs Stores

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Pharmerging market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmerging market?

Which is the largest regional market for Pharmerging market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmerging market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmerging market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Pharmerging Market
  • 2.2. Global Pharmerging Market, By Product, 2023 (US$ Million)
  • 2.3. Global Pharmerging Market, By Indication, 2023 (US$ Million)
  • 2.4. Global Pharmerging Market, By Distribution Channel, 2023 (US$ Million)
  • 2.5. Global Pharmerging Market, By Geography, 2023 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2023

3. Pharmerging Market: Competitive Analysis

  • 3.1. Market Positioning of Key Pharmerging Market Vendors
  • 3.2. Strategies Adopted by Pharmerging Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2023 Versus 2032

4. Pharmerging Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Pharmerging Market Value, 2022 - 2032, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Pharmerging Market: By Product, 2022-2032, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 5.3. Market Segmentation
    • 5.3.1. Pharmaceuticals
      • 5.3.1.1. Branded Prescription Drugs
      • 5.3.1.2. Generic Drugs
        • 5.3.1.2.1. Branded Generics
        • 5.3.1.2.2. Unbranded Generics
      • 5.3.1.3. OTC Drugs
    • 5.3.2. Healthcare
      • 5.3.2.1. Medical Devices
      • 5.3.2.2. Diagnostic Instruments
      • 5.3.2.3. Others (IT and Record Management)

6. Pharmerging Market: By Indication, 2022-2032, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 6.3. Market Segmentation
    • 6.3.1. Lifestyle Diseases
    • 6.3.2. Cancer and Autoimmune Diseases
    • 6.3.3. Infectious Diseases
    • 6.3.4. Others

7. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2023 Versus 2032
  • 7.3. Market Segmentation
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Retail Pharmacies
    • 7.3.4. E-commerce
    • 7.3.5. Drugs Stores

8. North America Pharmerging Market, 2022-2032, USD (Million)

  • 8.1. Market Overview
  • 8.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
  • 8.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
  • 8.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
  • 8.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 8.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 8.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 8.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 8.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 8.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 8.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

9. UK and European Union Pharmerging Market, 2022-2032, USD (Million)

  • 9.1. Market Overview
  • 9.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
  • 9.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
  • 9.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
  • 9.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 9.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 9.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

10. Asia Pacific Pharmerging Market, 2022-2032, USD (Million)

  • 10.1. Market Overview
  • 10.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
  • 10.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
  • 10.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
  • 10.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.4.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.4.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.5.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.5.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 10.5.1.6.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 10.5.1.6.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

11. Latin America Pharmerging Market, 2022-2032, USD (Million)

  • 11.1. Market Overview
  • 11.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
  • 11.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
  • 11.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
  • 11.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 11.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 11.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 11.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 11.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 11.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 11.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

12. Middle East and Africa Pharmerging Market, 2022-2032, USD (Million)

  • 12.1. Market Overview
  • 12.2. Pharmerging Market: By Product, 2022-2032, USD (Million)
  • 12.3. Pharmerging Market: By Indication, 2022-2032, USD (Million)
  • 12.4. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
  • 12.5.Pharmerging Market: By Region, 2022-2032, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 12.5.1.1.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 12.5.1.1.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 12.5.1.2.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 12.5.1.2.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. Pharmerging Market: By Product, 2022-2032, USD (Million)
        • 12.5.1.3.2. Pharmerging Market: By Indication, 2022-2032, USD (Million)
        • 12.5.1.3.3. Pharmerging Market: By Distribution Channel, 2022-2032, USD (Million)

13. Company Profile

  • 13.1. Abbott Laboratories
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. Koninklijke Philips N.V.
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. F. Hoffmann-La Roche Ltd.
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Merck & Co., Inc.
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Novartis AG
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Johnson & Johnson
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives
  • 13.7. Teva Pharmaceutical Industries Ltd.
    • 13.7.1. Company Overview
    • 13.7.2. Financial Performance
    • 13.7.3. Product Portfolio
    • 13.7.4. Strategic Initiatives
  • 13.8. AstraZeneca
    • 13.8.1. Company Overview
    • 13.8.2. Financial Performance
    • 13.8.3. Product Portfolio
    • 13.8.4. Strategic Initiatives
  • 13.9. GlaxoSmithKline plc
    • 13.9.1. Company Overview
    • 13.9.2. Financial Performance
    • 13.9.3. Product Portfolio
    • 13.9.4. Strategic Initiatives
  • 13.10. Lupin
    • 13.10.1. Company Overview
    • 13.10.2. Financial Performance
    • 13.10.3. Product Portfolio
    • 13.10.4. Strategic Initiatives
  • 13.11. Tata Consultancy Services Ltd.
    • 13.11.1. Company Overview
    • 13.11.2. Financial Performance
    • 13.11.3. Product Portfolio
    • 13.11.4. Strategic Initiatives
  • 13.12. Sun Pharmaceutical Industries Ltd.
    • 13.12.1. Company Overview
    • 13.12.2. Financial Performance
    • 13.12.3. Product Portfolio
    • 13.12.4. Strategic Initiatives
  • 13.13. Huadong Medicine Co., Ltd.
    • 13.13.1. Company Overview
    • 13.13.2. Financial Performance
    • 13.13.3. Product Portfolio
    • 13.13.4. Strategic Initiatives
  • 13.14. Other Notable Players
    • 13.14.1. Company Overview
    • 13.14.2. Financial Performance
    • 13.14.3. Product Portfolio
    • 13.14.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 2 Global Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 3 Global Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 4 Global Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 5 Global Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 6 Global Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 7 North America Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 8 North America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 9 North America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 10 North America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 11 North America Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 12 North America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 13 U.S. Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 14 U.S. Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 15 U.S. Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 16 U.S. Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 17 U.S. Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 18 U.S. Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 19 Canada Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 20 Canada Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 21 Canada Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 22 Canada Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 23 Canada Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 24 Canada Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 25 Rest of North America Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 26 Rest of North America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 27 Rest of North America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 28 Rest of North America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 29 Rest of North America Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 30 Rest of North America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 31 UK and European Union Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 32 UK and European Union Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 33 UK and European Union Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 34 UK and European Union Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 35 UK and European Union Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 36 UK and European Union Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 37 UK Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 38 UK Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 39 UK Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 40 UK Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 41 UK Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 42 UK Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 43 Germany Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 44 Germany Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 45 Germany Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 46 Germany Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 47 Germany Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 48 Germany Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 49 Spain Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 50 Spain Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 51 Spain Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 52 Spain Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 53 Spain Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 54 Spain Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 55 Italy Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 56 Italy Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 57 Italy Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 58 Italy Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 59 Italy Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 60 Italy Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 61 France Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 62 France Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 63 France Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 64 France Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 65 France Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 66 France Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 67 Rest of Europe Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 68 Rest of Europe Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 69 Rest of Europe Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 70 Rest of Europe Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 71 Rest of Europe Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 72 Rest of Europe Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 73 Asia Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 74 Asia Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 75 Asia Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 76 Asia Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 77 Asia Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 78 Asia Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 79 China Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 80 China Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 81 China Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 82 China Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 83 China Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 84 China Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 85 Japan Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 86 Japan Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 87 Japan Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 88 Japan Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 89 Japan Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 90 Japan Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 91 India Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 92 India Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 93 India Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 94 India Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 95 India Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 96 India Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 97 Australia Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 98 Australia Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 99 Australia Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 100 Australia Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 101 Australia Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 102 Australia Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 103 South Korea Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 104 South Korea Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 105 South Korea Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 106 South Korea Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 107 South Korea Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 108 South Korea Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 109 Latin America Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 110 Latin America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 111 Latin America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 112 Latin America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 113 Latin America Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 114 Latin America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 115 Brazil Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 116 Brazil Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 117 Brazil Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 118 Brazil Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 119 Brazil Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 120 Brazil Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 121 Mexico Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 122 Mexico Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 123 Mexico Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 124 Mexico Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 125 Mexico Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 126 Mexico Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 127 Rest of Latin America Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 128 Rest of Latin America Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 129 Rest of Latin America Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 130 Rest of Latin America Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 131 Rest of Latin America Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 132 Rest of Latin America Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 133 Middle East and Africa Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 134 Middle East and Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 135 Middle East and Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 136 Middle East and Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 137 Middle East and Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 138 Middle East and Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 139 GCC Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 140 GCC Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 141 GCC Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 142 GCC Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 143 GCC Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 144 GCC Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 145 Africa Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 146 Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 147 Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 148 Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 149 Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 150 Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)
  • TABLE 151 Rest of Middle East and Africa Pharmerging Market By Product, 2022-2032, USD (Million)
  • TABLE 152 Rest of Middle East and Africa Pharmerging Market By Pharmaceuticals, 2022-2032, USD (Million)

TABLE 153 Rest of Middle East and Africa Pharmerging Market By Generic Drugs, 2022-2032, USD (Million)

TABLE 154 Rest of Middle East and Africa Pharmerging Market By Healthcare, 2022-2032, USD (Million)

TABLE 155 Rest of Middle East and Africa Pharmerging Market By Indication, 2022-2032, USD (Million)

  • TABLE 156 Rest of Middle East and Africa Pharmerging Market By Distribution Channel, 2022-2032, USD (Million)

List of Figures

  • FIG. 1 Global Pharmerging Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Pharmerging Market: Quality Assurance
  • FIG. 5 Global Pharmerging Market, By Product, 2023
  • FIG. 6 Global Pharmerging Market, By Indication, 2023
  • FIG. 7 Global Pharmerging Market, By Distribution Channel, 2023
  • FIG. 8 Global Pharmerging Market, By Geography, 2023
  • FIG. 9 Market Geographical Opportunity Matrix - Global Pharmerging Market, 2023

FIG. 10Market Positioning of Key Pharmerging Market Players, 2023

FIG. 11Global Pharmerging Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032

  • FIG. 12 Global Pharmerging Market, By Product, 2023 Vs 2032, %
  • FIG. 13 Global Pharmerging Market, By Indication, 2023 Vs 2032, %
  • FIG. 14 Global Pharmerging Market, By Distribution Channel, 2023 Vs 2032, %
  • FIG. 15 U.S. Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 16 Canada Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 17 Rest of North America Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 18 UK Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 19 Germany Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 20 Spain Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 21 Italy Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 22 France Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 23 Rest of Europe Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 24 China Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 25 Japan Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 26 India Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 27 Australia Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 28 South Korea Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 29 Rest of Asia Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 30 Brazil Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 31 Mexico Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 32 Rest of Latin America Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 33 GCC Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 34 Africa Pharmerging Market (US$ Million), 2022 - 2032
  • FIG. 35 Rest of Middle East and Africa Pharmerging Market (US$ Million), 2022 - 2032